Key facts
- This page summarizes Sophie Mukadam's Form 3 filing for Benitec Biopharma Inc. (BNTC).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2025, 17:39.
Sophie Mukadam - 01 Jan 2025 Form 3 Insider Report for Benitec Biopharma Inc. (BNTC)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- BNTC
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Jan 2025, 17:39:57 UTC
- Next SEC filing
- 20 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Louis Rambo, Attorney-in-Fact for Sophie Mukadam
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sophie Mukadam filed Form 3 for Benitec Biopharma Inc. (BNTC) on 03 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BNTC
holding
Common Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,016
- Date
- 01 Jan 2025
- Ownership
- By spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNTC
holding
Derivative
Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 141
- Exercise price
- $50.66
- Footnotes
- F1
BNTC
holding
Derivative
Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,034
- Exercise price
- $79.90
- Footnotes
- F2
BNTC
holding
Derivative
Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,294
- Exercise price
- $3.91
- Footnotes
- F3
BNTC
holding
Derivative
Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $5.21
- Footnotes
- F4
BNTC
holding
Derivative
Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $12.00
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The stock options vested in three substantially equal installments on December 9, 2021, December 9, 2022 and December 9, 2023.
Footnote F2
The stock options vested in three substantially equal installments on June 14, 2022, June 14, 2023, and June 14, 2024.
Footnote F3
Stock options for 1,764 shares vested on June 13, 2024. The remainder of the stock options will vest in two substantially equal installments on June 13, 2025 and June 13, 2026.
Footnote F4
The stock options will vest in three substantially equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
Footnote F5
The stock options will vest in sixteen substantially equal quarterly installments commencing on March 31, 2025.
SEC remarks
Exhibit 24 - Power of Attorney